Calico Biosystems News

July 2026:

Calico Biosystems named one of 3 official finalists for Top100 Swiss Startup Award — Newcomer of the Year 2026.
Top100 Public Voting: The 3 Finalists for Top100 Newcomer of the Year 2026

June 2026:

Commercial Validation: Calico Biosystems has completed a series of landmark studies with a selected group of globally recognized partners across pharma, biotech, and contract research organizations.

June 2026:

Calico Biosystems made it into the Top 100 Swiss Startup 2026! 🎉
We’ve been selected by a jury of 100 investors and startup experts across Switzerland. Now it’s your turn to vote for the next rising star of the Swiss startup ecosystem. Cast your vote here:

👉 https://lnkd.in/ezJcRwZh

Just log in with LinkedIn and click “Vote for this startup” on Calico Biosystems profile. Takes 30 seconds, and every vote genuinely matters. Support Swiss innovation and choose Calico Biosystems as your favorite startup!

Voting closes July 19.

May 2026:

Strategic Collaboration: Calico Biosystems and Taconic Biosciences have initiated a collaboration bridging native patient biology and systemic in vivo data. Calico’s NAM platform generates efficacy and multi-omics insights directly from intact native patient tumors, preserving the complexity of the human tumor microenvironment. Together, the two companies help sponsors make more informed translational decisions, de-risk clinical trials, and accelerate the development of better therapies for patients.

April 2026:

Regulatory Tailwinds: There is an industry shift toward NAMs (New Approach Methodologies) accelerated by the FDA Modernization Act 2.0 and 3.0. Calico Biosystems is actively engaged in this transition, recently contributing to the evolving regulatory landscape by submitting formal comments on the FDA’s March draft guidance.